作者: Y.Y.B. Lee , A. Vellido , W. El-Deredy , S.P.J. Kirby , P.J.G. Lisboa
DOI: 10.1049/IC:19981036
关键词:
摘要: There are currently few commercially available clinical products with neural network components-in fact only one has gained FDA approval, and none have yet been certified by the MDA. A major step in certification process is proving integrity of component, which cannot be done reference to substantially equivalent because they do not exist. Consequently, case for use new technology made explicitly, recourse best practice its design evaluation. This paper discusses networks medical applications, a study from magnetic resonance spectroscopy (MRS).